Cefprozil
Based on 1 Customer Validation
Cefprozil is a second-generation cephalosporin type antibiotic. Cefprozil exhibits broad-spectrum antibacterial activity, and is orally active. Cefprozil can be used for the study of pharyngitis, tonsillitis, otitis media, and uncomplicated skin infections.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 99.82%
- No. CAS: 92665-29-7
- Fòrmula: C18H19N3O5S
- Peso molecular:389.43
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Ver todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
Descripciòn
IC50 & Target
|
β-lactam |
In Vitro
Cefprozil inhibits S. pyogenes, S. pneumoniae, S. agalactiae, S. aureus (methicillin-susceptible), H. influenzae, M. catarrhalis, E. coli with MIC90s of 0.04, 0.23, 0.3, 1.4, 6.7, 4.5, 12.2 mg/L, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 92665-29-7
-
Appearance Solid
-
Peso molecular 389.43
-
Fòrmula C18H19N3O5S
-
Color White to off-white
-
SMILES
OC(C(N1[C@@]2([H])[C@H](NC([C@@H](C3=CC=C(O)C=C3)N)=O)C1=O)=C(CS2)/C=C/C)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Pureza y Documentación
-
Ficha de datos (268 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. J C Fung-Tom, et al. Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides. Antimicrob Agents Chemother. 1995 Feb;39(2):533-8. [Content Brief]
[2]. Wiseman LR, et al., Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential. Drugs. 1993 Feb;45(2):295-317. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)